CCR5 Inhibitor Sarac Cleared for Trials in China, Phase 2 in MS Planned

An expert talk on neuroimmunology covers how myelin-reactive T cells home to bone marrow and drive CCR5-mediated myeloid skewing of hematopoietic stem cells in multiple sclerosis, plus bone-marrow mechanisms in intracerebral hemorrhage and stroke-associated pneumonia involving CCR2-driven HSC migration to the lung. A CCR5 inhibitor, Sarac, developed with the Shanghai Institute of Materia Medica, has been approved by China's FDA to enter clinical trials, with a phase 2 trial (Sarac MS) in multiple sclerosis planned next.